BioStock: Aptahem signs agreement with CRO for phase I studies

Aptahem has entered into an agreement with a clinical contract research organisation in the Netherlands for the implementation of the upcoming phase I sepsis study with the drug candidate Apta-1. The news followed the earlier announcement that Aptahem has joined a new research consortium that will evaluate novel treatments to reduce inflammation in cardiovascular diseases and breast cancer, again focusing on Apta-1.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/aptahem-signs-agreement-with-cro-for-phase-i-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/